US patent for needle-free penile syringe:
This article was originally published in Clinica
Executive Summary
Medi-Ject has received a US patent covering its needle-free syringe for delivering drugs into the penis. The new device for so-called intracorporal delivery is a modification of the company's needle-free technology which is already available commercially for the administration of insulin and growth hormones. The modified Medi-Jector system would encourage significantly more men to take advantage of erectile dysfunction therapy, said the Minneapolis, Minnesota-based company. In addition to starting Phase I/II clinical studies to assess the safety and efficacy of needle-free delivery, Medi-Ject plans to test an approved drug.
You may also be interested in...
New EU Filings
Obecabtagene autoleucel, Autolus Therapeutics’s investigational treatment for relapsed or refractory B cell precursor acute lymphoblastic leukemia, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.
BMS Has A Strong Pipeline, But Access Challenges Remain
Bristol Myers Squibb’s head of major markets, Monica Shaw, wants to improve patients’ access to lifesaving therapies. And the group has several new products ready to roll.
Novartis Hires Ex-BMS Chief As It Pursues US Growth Strategy
The Swiss pharma company is looking to tap into the experience of ex-BMS leader Giovanni Caforio to help further it US-first commercial strategy.